Natera, Inc. (NASDAQ:NTRA - Get Free Report) insider Solomon Moshkevich sold 1,639 shares of the company's stock in a transaction that occurred on Tuesday, February 3rd. The shares were sold at an average price of $230.77, for a total transaction of $378,232.03. Following the transaction, the insider owned 137,847 shares in the company, valued at $31,810,952.19. The trade was a 1.18% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website.
Solomon Moshkevich also recently made the following trade(s):
- On Monday, February 2nd, Solomon Moshkevich sold 3,000 shares of Natera stock. The shares were sold at an average price of $231.44, for a total transaction of $694,320.00.
- On Wednesday, January 28th, Solomon Moshkevich sold 1,200 shares of Natera stock. The shares were sold at an average price of $237.66, for a total value of $285,192.00.
- On Tuesday, January 27th, Solomon Moshkevich sold 1,013 shares of Natera stock. The stock was sold at an average price of $240.53, for a total value of $243,656.89.
- On Wednesday, January 21st, Solomon Moshkevich sold 293 shares of Natera stock. The shares were sold at an average price of $235.00, for a total value of $68,855.00.
- On Tuesday, January 20th, Solomon Moshkevich sold 23,205 shares of Natera stock. The shares were sold at an average price of $234.74, for a total value of $5,447,141.70.
- On Friday, January 2nd, Solomon Moshkevich sold 2,951 shares of Natera stock. The stock was sold at an average price of $228.95, for a total value of $675,631.45.
- On Friday, December 12th, Solomon Moshkevich sold 4,692 shares of Natera stock. The stock was sold at an average price of $230.76, for a total value of $1,082,725.92.
- On Monday, December 1st, Solomon Moshkevich sold 3,000 shares of Natera stock. The stock was sold at an average price of $238.15, for a total transaction of $714,450.00.
Natera Trading Down 9.7%
NTRA opened at $205.61 on Thursday. Natera, Inc. has a 12-month low of $125.38 and a 12-month high of $256.36. The firm has a 50 day moving average of $234.95 and a two-hundred day moving average of $195.74. The firm has a market capitalization of $28.44 billion, a PE ratio of -89.79 and a beta of 1.64.
Natera (NASDAQ:NTRA - Get Free Report) last released its quarterly earnings data on Friday, November 7th. The medical research company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.25). Natera had a negative net margin of 14.61% and a negative return on equity of 25.07%. The business had revenue of $592.18 million during the quarter, compared to analysts' expectations of $514.55 million. During the same period last year, the company earned ($0.26) earnings per share. The firm's revenue was up 34.7% on a year-over-year basis. As a group, analysts predict that Natera, Inc. will post -1.49 EPS for the current fiscal year.
Natera News Summary
Here are the key news stories impacting Natera this week:
- Positive Sentiment: Natera submitted a Premarket Approval (PMA) to the FDA for Signatera CDx to detect minimal residual disease (MRD) in bladder cancer after positive phase‑3 results — a regulatory win that could create a companion diagnostic revenue stream and improve clinical adoption/reimbursement if approved. Read More.
- Neutral Sentiment: Multiple non‑executive insiders also sold shares this week (Solomon Moshkevich and John Fesko each trimmed small single‑digit percentages of their holdings). These appear to be modest, routine dispositions versus strategic exits but add to selling pressure. Read More.
- Negative Sentiment: CEO Steven Chapman sold 85,299 shares on Feb 2 (~40% reduction in his holding) for a proceeds block of roughly $19.7M — a material insider disposition that investors often view negatively. Read More.
- Negative Sentiment: Additional executive sales this week: CEO Chapman sold another 4,725 shares (Feb 3) and CFO Michael Burkes Brophy sold 6,939 shares (Feb 3), each trimming double‑digit or mid‑single digit ownership percentages — reinforcing near‑term downward pressure on the stock. Read More. Read More.
Analysts Set New Price Targets
Several equities analysts have recently issued reports on the company. Barclays boosted their price objective on Natera from $230.00 to $270.00 and gave the company an "overweight" rating in a report on Monday, December 15th. Weiss Ratings reissued a "sell (d-)" rating on shares of Natera in a report on Thursday, January 22nd. TD Cowen reaffirmed a "buy" rating on shares of Natera in a research note on Wednesday, January 7th. Canaccord Genuity Group reiterated a "buy" rating on shares of Natera in a research note on Monday, January 12th. Finally, Citigroup began coverage on shares of Natera in a report on Wednesday, January 7th. They set a "buy" rating and a $300.00 price target on the stock. One investment analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Natera currently has a consensus rating of "Moderate Buy" and a consensus price target of $249.20.
Check Out Our Latest Analysis on Natera
Hedge Funds Weigh In On Natera
Several hedge funds and other institutional investors have recently added to or reduced their stakes in NTRA. Horizon Investments LLC purchased a new position in Natera in the 3rd quarter valued at about $32,000. Hilltop National Bank purchased a new position in shares of Natera in the second quarter valued at approximately $33,000. Sound Income Strategies LLC boosted its stake in shares of Natera by 95.7% in the third quarter. Sound Income Strategies LLC now owns 225 shares of the medical research company's stock worth $39,000 after acquiring an additional 110 shares during the last quarter. Flagship Harbor Advisors LLC purchased a new stake in shares of Natera during the fourth quarter worth approximately $41,000. Finally, Quent Capital LLC acquired a new position in Natera in the 3rd quarter valued at $46,000. 99.90% of the stock is owned by hedge funds and other institutional investors.
About Natera
(
Get Free Report)
Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.
Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
